OREANDA-NEWS Ultrafast insulin "Fiasp" produced by Danish Novo Nordisk is regularly supplied to the Russian market, while its domestic analogues with the same international nonproprietary name (INN) insulin aspart are also available to patients, the Ministry of Industry and Trade reported.

Earlier on Friday, the Kommersant newspaper reported that adult diabetic patients faced difficulties in obtaining superfast insulin Fiasp, after injection of which they can almost immediately take food.

"According to the data available to the Ministry of Industry and Trade of Russia, the original drug Fiasp produced by Novo Nordisk (INN insulin aspart) is regularly supplied to the Russian market: the last major delivery (more than 90 thousand packages) was in January this year. At the same time, the drug has several biosimilars at once, including domestic production," the ministry said.

Among such analogues are Rinfast and Rinfast Nick, which are produced by the domestic company Geropharm (delivery of more than 37 thousand packages in January and 38 thousand in March, respectively), as well as Rosinsulin Aspart R produced by the Medsintez plant (more than 86 thousand packages in March). The ministry stressed that domestic manufacturers have sufficient production capacities to meet the annual needs of the country's healthcare system.
In addition, all drugs with INN insulin aspart, including domestic production, are widely represented in Russian pharmacies: according to the CRPT, they can be purchased in almost 8 thousand points. There are also currently residues of medicines with this INN with a total volume of more than 1 million packages.